ProQR Therapeutics PRQR
NASDAQ PRQR
$1.36 +0.10 (+7.78%)
As of: Nov 12, 2026 · 11:03 AM EST

ProQR Therapeutics (PRQR) Return on Sales [ROS] (2013 - 2026)

Updated

ProQR Therapeutics (PRQR) posted Return on Sales [ROS] of -100.72% for the quarter ended Jun 30, 2026, up 220.19 percentage points from -320.91% a year earlier and up 570.65 percentage points from the prior quarter.

Analysis

ProQR Therapeutics (PRQR) Return on Sales [ROS] (2013 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Return on Sales [ROS] at ProQR Therapeutics was -233.85%, up 20.87 percentage points year-over-year; for the year ended Dec 31, 2025, it was -273.14%, down 111.96 percentage points from the prior year.

  • Annual Return on Sales [ROS] shows a four-year change of +4012.25 percentage points (years ended Dec 2021 to Dec 2025).
  • In prior years, ProQR Therapeutics' Return on Sales [ROS] was -161.18% in the year ended Dec 31, 2024 (+327.90 pp), -489.09% in the year ended Dec 31, 2023 (+1323.91 pp), -1812.99% in the year ended Dec 31, 2022 (+2472.40 pp) and -4285.39% in the year ended Dec 31, 2021.
  • The figure for the quarter ended Jun 30, 2026 stands as the highest quarterly Return on Sales [ROS] since the quarter ended Jun 30, 2024.
  • On a year-over-year basis, Return on Sales [ROS] increased in three of the last eight quarters, with an average year-over-year change of -48.60 percentage points.
  • The strongest year-over-year quarter for Return on Sales [ROS] in the past five years was the quarter ended Dec 31, 2022, with a gain of 5519.65 percentage points; the weakest was the quarter ended Sep 30, 2022, with a drop of 765.88 percentage points.
  • According to Business Quant data, Return on Sales [ROS] for the three prior quarters was -671.37% (quarter ended Mar 31, 2026), -194.05% (quarter ended Dec 31, 2025) and -391.53% (quarter ended Sep 30, 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 ProQR Therapeutics 138.02 Mn -322.63 Mn - -100.72%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -100.72%
Mar 31, 2026 -671.37%
Dec 31, 2025 -194.05%
Sep 30, 2025 -391.53%
Jun 30, 2025 -320.91%
Mar 31, 2025 -239.34%
Dec 31, 2024 -234.06%
Sep 30, 2024 -226.80%
Jun 30, 2024 -57.10%
Mar 31, 2024 -181.46%
Dec 31, 2023 -190.86%
Sep 30, 2023 -539.49%
Jun 30, 2023 -731.20%
Mar 31, 2023 -1,433.44%
Dec 31, 2022 -1,730.56%
Sep 30, 2022 -2,435.26%
Jun 30, 2022 -1,702.37%
Mar 31, 2022 -1,508.32%
Dec 31, 2021 -7,250.21%
Sep 30, 2021 -1,669.38%
API Access

ProQR Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=PRQR&period=max&api_key=YOUR_API_KEY